Puma Biotechnology's Competitors, Revenue, Number of Employees, Funding, Acquisitions & News - Owler Company Profile
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
PUMA is a cellular target of miR-BART5. (A) Target site of miR-BART5 in... | Download Scientific Diagram
EMA's oncology advisory group to render opinion on Puma Bio's neratinib next month; shares slip 2% after hours By Seeking Alpha
Puma brings back its RS-Computer smart running shoe from the 1980s
Puma Biotechnology Enters into Collaboration with Strata Oncology
Puma Bio to adjust proposed labeling for neratinib after meeting with CHMP oncology advisory group; shares up 2% after hours By Seeking Alpha
Puma Biotechnology
Puma Biotechnology enters into a collaborative agreement with Strata Oncology
Puma Biotech: Wounded Predator Ready To Jump Back (NASDAQ:PBYI) | Seeking Alpha
Press Releases — Strata Oncology
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today | The Motley Fool
Puma Biotechnology
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma
Puma Biotechnology
2E) SAO/
Knight Therapeutics licences cancer drug from Puma Biotechnology
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Puma Biotechnology
Puma Logo clipart - Blue, Text, Font, transparent clip art
Victory for Puma as FDA approves breast cancer drug -
Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial) | Business Wire
Puma sells commercialization rights to Nerlynx in Latin America
Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report
